Analyst Price Target News: Coinbase, Alnylam – August 4th, 2025

By: Matthew Otto

Coinbase Faces Decline in Q2 Profit Amid Slower Trading Activity

Coinbase reported a drop in second-quarter adjusted profit, with earnings declining to $33.2 million, or $0.12 per share, compared to $294.4 million, or $1.1 per share, in the same quarter last year. The result fell short of the $1.51 per share expected by analysts, according to data from FactSet. Quarterly revenue reached $1.5 billion, missing the consensus estimate of $1.59 billion and marking a decline of roughly 26% from Q1.

Coinbase saw some resilience in its subscription and services revenue, which rose 9.5% year-over-year to approximately $656 million. Interest income related to stablecoins was a contributor, increasing to $332 million from $240 million a year earlier.

Several analysts expressed caution about Coinbase’s valuation and growth trajectory. Morningstar analyst Michael Miller wrote, “We see the shares as significantly overvalued. We believe that the market is projecting too much future growth for the firm.” Similarly, analyst Mike Colonnese at H.C. Wainwright noted that “investor enthusiasm had reached a ‘fever pitch’ heading into last night’s results, as valuation has detached from underlying fundamentals.”

Analyst Ratings Diverge Following Q2 Earnings Miss

Compass Point analyst Ed Engel downgraded from Neutral to Sell and the price target from $330 to $248.
Benchmark analyst Mark Palmer reiterated a Buy rating but maintained a price target of $421.00.

Which Analyst has the best track record to show on COIN?

Analyst Mike Colonnese (HC WAINWRIGHT) currently has the highest performing score on COIN with 12/13 (92.31%) price target fulfillment ratio. His price targets carry an average of $-88.96 (-22.87%) potential downside. Coinbase stock price reaches these price targets on average within 97 days.

Alnylam Sees Growth in Q2 2025 as More Patients Start Treatment for Rare Heart Disease

Alnylam Pharmaceuticals reported $672 million in product sales for the second quarter of 2025, marking a 64% increase compared to the same period in 2024. This increase was primarily associated with AMVUTTRA, a treatment for transthyretin amyloidosis (ATTR), a rare condition that affects the nerves or heart.

Sales of AMVUTTRA reached $492 million in the quarter. By the end of June, approximately 1,400 patients with the heart-related form of the disease (ATTR-CM) had started the treatment. AMVUTTRA was also approved in additional regions during the quarter, including the European Union, Brazil, the United Kingdom, and Japan. ONPATTRO, another approved treatment for ATTR, generated $53 million in revenue. Two other rare disease treatments, GIVLAARI and OXLUMO, brought in a combined $128 million, representing a 24% increase year-over-year.

ATTR is caused by a buildup of abnormal transthyretin protein in the body. It can lead to damage in the heart (ATTR-CM) or nerves (hATTR-PN). According to estimates, over 400,000 people globally may have the cardiac form of the condition, though many remain undiagnosed.

Following the results from the first half of the year, Alnylam raised its full-year revenue forecast to a range of $2.65 billion to $2.8 billion.

Analyst Upgrades Signal Improving Outlook

Oppenheimer analyst Leland Gershell upgraded from Perform to Outperform and set a price target of $490.
Wolfe Research analyst Andy Chen upgraded from Underperform to Peer Perform.

Which Analyst has the best track record to show on ALNY?

Analyst Maury Raycroft (JEFFERIES) currently has the highest performing score on ALNY with 8/8 (100%) price target fulfillment ratio. His price targets carry an average of $59.87 (18.47%) potential upside. Alnylam Pharmaceuticals stock price reaches these price targets on average within 108 days.

Vontier Posts Q2 2025 Growth with Strong Sales Across Core Segments

Vontier reported second quarter 2025 revenue of $773.5 million, up 11.1% from the same period last year and ahead of the $734.5 million consensus estimate. Core sales grew 10.8%, driven by strength in Environmental & Fueling Solutions and Mobility Technologies. Environmental & Fueling Solutions revenue increased 16.2% to $361.6 million, supported by demand for fuel dispensing equipment and environmental products.

Segment operating profit rose 18.4% to $105.7 million, with a margin increase of 50 basis points to 29.2%. Mobility Technologies posted revenue of $280.2 million, up 17.9%, and segment profit rose 29.9% to $53.5 million, with a 180-basis point increase in margin to 19.1%. Repair Solutions held steady at $150.8 million in revenue, though segment profit declined 2.2% to $31.4 million, with margins contracting by 50 basis points.

Company-wide operating profit rose 19.5% year-over-year to $136.4 million, with an operating margin of 17.6%. Adjusted operating profit was $163.4 million, with a 21.1% margin. Net income reached $91.9 million, translating to earnings of $0.62 per diluted share. Adjusted EPS of $0.79 came in $0.07 ahead of the $0.72 analyst estimate. Cash flow from operations was $100 million, with adjusted free cash flow of $89 million, representing a 76% conversion rate.

Looking ahead, Vontier guided Q3 2025 earnings to $0.74 to $0.78 per share, slightly below the $0.78 consensus, on revenue of $745 to $755 million versus the $755.4 million estimate. For the full year, earnings guidance was raised to $3.1 to $3.2 per share, above the $3.12 consensus midpoint, while revenue is projected between $3.02 billion and $3.07 billion, compared to consensus of $3.021 billion.

Analyst Lifts Price Target to Following Q2 Beat and Full-Year Outlook

Baird analyst Robert Mason maintained a Neutral rating and raised the price target from $40 to $45.

Which Analyst has the best track record to show on VNT?

Analyst Robert Mason (BAIRD) currently has the highest performing score on VNT with 5/7 (71.43%) price target fulfillment ratio. His price targets carry an average of $2.75 (6.83%) potential upside. Vontier stock price reaches these price targets on average within 128 days.